

Umang Swami

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8864925/publications.pdf>

Version: 2024-02-01

108
papers

2,045
citations

394421

19
h-index

276875

41
g-index

108
all docs

108
docs citations

108
times ranked

2364
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	1.6	580
2	Systemic Therapy for Melanoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 3947-3970.	1.6	190
3	Advanced Prostate Cancer: Treatment Advances and Future Directions. <i>Trends in Cancer</i> , 2020, 6, 702-715.	7.4	122
4	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 3978-3992.	1.6	121
5	Recent Advances in the Management of Metastatic Prostate Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 45-55.	2.9	75
6	Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis. <i>Current Drug Targets</i> , 2013, 14, 777-797.	2.1	75
7	Eribulinâ€”A review of preclinical and clinical studies. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 163-184.	4.4	72
8	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. <i>European Urology</i> , 2020, 78, 652-656.	1.9	64
9	Eribulin in Cancer Treatment. <i>Marine Drugs</i> , 2015, 13, 5016-5058.	4.6	53
10	Advanced stage melanoma therapies: Detailing the present and exploring the future. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 99-111.	4.4	48
11	Immune Checkpoint Inhibitors in Prostate Cancer. <i>Cancers</i> , 2021, 13, 2187.	3.7	48
12	Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. <i>Annals of Translational Medicine</i> , 2019, 7, S18-S18.	1.7	44
13	Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3093-3093.	1.6	33
14	Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase Ib study. <i>Oncotarget</i> , 2017, 8, 89182-89193.	1.8	33
15	Ipilimumab-induced hypophysitis, a single academic center experience. <i>Pituitary</i> , 2019, 22, 488-496.	2.9	28
16	Harnessing DNA Replication Stress for Novel Cancer Therapy. <i>Genes</i> , 2020, 11, 990.	2.4	26
17	Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. <i>Cancers</i> , 2019, 11, 1950.	3.7	24
18	Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100325.	1.7	24

#	ARTICLE	IF	CITATIONS
19	Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. <i>Annals of Translational Medicine</i> , 2021, 9, 1033-1033.	1.7	23
20	Current status of intralesional agents in treatment of malignant melanoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1038-1038.	1.7	21
21	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	3.7	19
22	Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5072-5072.	1.6	17
23	A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas. <i>Cancers</i> , 2018, 10, 53.	3.7	16
24	Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	1.3	15
25	<p>Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3741-3749.	1.9	15
26	Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma. , 2021, 9, e001781.		15
27	Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 643-647.	1.2	13
28	Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. <i>Oncologist</i> , 2021, 26, 1006-e2129.	3.7	13
29	The dark side of immunotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 1041-1041.	1.7	12
30	Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-“PD-L1 Immunotherapy Be Administered after Anti-“PD-1-“Related Immune Toxicities?. <i>Journal of Thoracic Oncology</i> , 2018, 13, e102-e103.	1.1	11
31	Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 1507-1517.	1.9	11
32	Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies. <i>Antibiotics</i> , 2020, 9, 740.	3.7	11
33	Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. <i>Drugs</i> , 2021, 81, 191-206.	10.9	11
34	Toxicities with targeted therapies after immunotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 600-604.	1.2	10
35	Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. <i>Journal of Immunotherapy</i> , 2018, 41, 359-360.	2.4	10
36	A Retrospective Analysis of Clinical Trial Accrual of Patients Presented in a Multidisciplinary Tumor Board at a Tertiary Health Care Center and Associated Barriers. <i>Oncology Research and Treatment</i> , 2020, 43, 196-203.	1.2	10

#	ARTICLE	IF	CITATIONS
37	Experience With Vena Cava Filters at a Large Community Hospital and Level-I Trauma Center. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 546-552.	1.7	9
38	Identification of Somatic Gene Signatures in Circulating <scp>Cell-Free DNA</scp> Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. <i>Oncologist</i> , 2021, 26, 751-760.	3.7	9
39	Eribulin in non-small cell lung cancer: challenges and potential strategies. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 495-508.	4.1	8
40	Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 335-341.	2.4	8
41	Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response. <i>Journal of Thoracic Oncology</i> , 2018, 13, e183-e184.	1.1	7
42	Current management of metastatic castration-sensitive prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100384.	1.7	7
43	Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 205, 709-717.	0.4	7
44	Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2021, 13, 1489.	3.7	7
45	Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. <i>Oncologist</i> , 2022, 27, 220-227.	3.7	5
46	Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: A single institution experience from 1999 to 2010. <i>Gynecologic Oncology</i> , 2013, 131, 163-168.	1.4	4
47	Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. <i>European Urology</i> , 2020, 77, 22-23.	1.9	4
48	Landmark Series on Disparities in Surgical Oncology: Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6986-6993.	1.5	4
49	Prognostic markers for progression free survival (PFS) to anti PD-1 therapies in metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21527-e21527.	1.6	4
50	Clinical outcomes with early-elective discontinuation of PD-1 inhibitors (PDi) at one year in patients (pts) with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10048-10048.	1.6	4
51	Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100205.	1.7	3
52	The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 147-150.	2.4	3
53	Immunotherapy and fatigue: what we know and what we don't know. <i>Oncotarget</i> , 2021, 12, 719-720.	1.8	3
54	Abstract C216: Phase 1, first-in-human, dose-escalation study of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies. <i>Molecular Cancer Therapeutics</i> , 2009, 8, C216-C216.	4.1	3

#	ARTICLE	IF	CITATIONS
55	A phase Ib/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AtezoVax).. Journal of Clinical Oncology, 2020, 38, TPS382-TPS382.	1.6	3
56	The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma. Translational Cancer Research, 2019, 8, E1-E6.	1.0	3
57	Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. European Urology Focus, 2023, 9, 106-109.	3.1	3
58	Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. Journal of Geriatric Oncology, 2020, 11, 724-726.	1.0	2
59	Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics, 2020, 21, 75-81.	1.3	2
60	Cancer immunotherapy: recent advances and challenges. Annals of Translational Medicine, 2021, 9, 1032-1032.	1.7	2
61	Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E) after a prior NHT in patients (Pts) with metastatic prostate cancer (mPC): Results from a real-world dataset.. Journal of Clinical Oncology, 2020, 38, 5537-5537.	1.6	2
62	Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 716-716.	1.6	2
63	Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion. Journal of Thoracic Oncology, 2018, 13, e129-e130.	1.1	1
64	Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma. Case Reports in Oncological Medicine, 2019, 2019, 1-5.	0.3	1
65	A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 567-578.	2.3	1
66	Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer. JAMA Oncology, 2020, 6, 225.	7.1	1
67	Quest for Ideal Composite Biomarkers for Response to Immunotherapies. Clinical Cancer Research, 2020, 26, 5059-5061.	7.0	1
68	Phase I with expansion clinical trial of seleno-L-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside.. Journal of Clinical Oncology, 2021, 39, 322-322.	1.6	1
69	Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.. Journal of Clinical Oncology, 2021, 39, 135-135.	1.6	1
70	Recent Advances in the Treatment of Metastatic Prostate Cancer. Advances in Oncology, 2021, 1, 263-272.	0.2	1
71	Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA).. Journal of Clinical Oncology, 2021, 39, 5058-5058.	1.6	1
72	Editorial Comment. Journal of Urology, 2021, 206, 1429-1429.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Marine Sponge Derived Eribulin in Preclinical and Clinical Studies for Cancer. , 2015, , 59-100.		1
74	Clinical outcome for patients with metastatic colorectal cancer (mCRC) enrolled in phase I clinical trials: Single institution experience.. Journal of Clinical Oncology, 2013, 31, e13550-e13550.	1.6	1
75	Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report. Cancer Treatment and Research Communications, 2021, 29, 100480.	1.7	1
76	Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations. American Journal of Translational Research (discontinued), 2021, 13, 7427-7439.	0.0	1
77	Cytomegalovirus and Human Herpes Virus-6 Reactivation Following Tandem Transplantation Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma (MM). Biology of Blood and Marrow Transplantation, 2016, 22, S177-S178.	2.0	0
78	Gastrointestinal stromal tumors“are we stuck and the way forward. Translational Gastroenterology and Hepatology, 2017, 2, 93-93.	3.0	0
79	Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS). Annals of Oncology, 2019, 30, v379.	1.2	0
80	Ideal Glucocorticoid Regimen With Abiraterone Acetate. JAMA Oncology, 2019, 5, 1167.	7.1	0
81	The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin“ineligible Patients with Muscle“invasive Localized Urothelial Carcinoma. Oncologist, 2019, 24, 580-583.	3.7	0
82	Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA).. Journal of Clinical Oncology, 2021, 39, 256-256.	1.6	0
83	Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA).. Journal of Clinical Oncology, 2021, 39, 162-162.	1.6	0
84	Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC).. Journal of Clinical Oncology, 2021, 39, 17-17.	1.6	0
85	Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients.. Journal of Clinical Oncology, 2021, 39, 156-156.	1.6	0
86	Association of circulating tumor cells (CTC) with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort.. Journal of Clinical Oncology, 2021, 39, 59-59.	1.6	0
87	Comprehensive genomic profiling of matched primary prostate cancer tissue and cell-free DNA (cfDNA) to assess ontogeny of BRCA1/BRCA2 mutations.. Journal of Clinical Oncology, 2021, 39, 166-166.	1.6	0
88	Combination therapy with avelumab (Ave) and cabozantinib (Cabo) in patients (pts) with newly diagnosed metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2021, 39, 334-334.	1.6	0
89	Reply to Saima Koochar, Nicholas Mitsiades“ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652“6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?. European Urology, 2021, 79, e94-e95.	1.9	0
90	Correlation of baseline circulating tumor cells (CTC) and associated genomic profile with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort.. Journal of Clinical Oncology, 2021, 39, 5077-5077.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB).. Journal of Clinical Oncology, 2021, 39, 2599-2599.	1.6	0
92	Genomic predictors of response to PD-1 axis inhibitors in metastatic urothelial cancer (mUC) patients using machine learning analysis of tissue comprehensive genomic profiling (CGP).. Journal of Clinical Oncology, 2021, 39, 4542-4542.	1.6	0
93	Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. European Urology Oncology, 2021, 4, 553-557.	5.4	0
94	Drug development in metastatic prostate cancer: lessons from ACIS. Lancet Oncology, The, 2021, 22, 1487-1488.	10.7	0
95	Developing a novel prognostic model to predict overall survival (OS) and 90 day mortality rate (90DM) for metastatic colorectal cancer (mCRC) patients in phase I trials.. Journal of Clinical Oncology, 2015, 33, e14618-e14618.	1.6	0
96	Collection of Peripheral Blood Stem Cells in Patients with Multiple Myeloma after Stem Cell Transplant: A Single Institution Experience. Blood, 2015, 126, 5435-5435.	1.4	0
97	Immunomodulation of pembrolizumab (pembro) treated metastatic melanoma patients (pts) after progression with sequential temozolomide (TMZ): A case series.. Journal of Clinical Oncology, 2017, 35, 123-123.	1.6	0
98	Risks and benefits of phase I trials: Eighteen-year experience from a single institution.. Journal of Clinical Oncology, 2017, 35, e18146-e18146.	1.6	0
99	Abstract B23: A pilot study targeting angiogenesis using bevacizumab combined with gemcitabine/docetaxel and valproic acid (VPA), a histone deacetylase inhibitor (HDACi), in advanced soft tissue sarcomas (STS). , 2018, , .		0
100	Response to systemic therapy and survival outcomes in de-novo (D1) metastatic castration-sensitive prostate cancer (mCSPC) versus mCSPC with prior local therapy (D0).. Journal of Clinical Oncology, 2020, 38, 46-46.	1.6	0
101	Comparative effectiveness of second-line (2L) single-agent atezolizumab (A), nivolumab (N), and pembrolizumab (P) in patients (Pts) with locally advanced or metastatic urothelial cancer (aUC) who progressed on platinum-based systemic chemotherapy (plat-chemo): Results from a real-world dataset.. Journal of Clinical Oncology, 2020, 38, 5032-5032.	1.6	0
102	Genomic alterations associated with the progression from castration-sensitive to castration-resistant metastatic prostate cancer based on machine learning analysis of cell-free DNA genomic profile.. Journal of Clinical Oncology, 2020, 38, e17596-e17596.	1.6	0
103	Identification of genomic alterations in signaling pathways associated with poor survival in newly diagnosed metastatic prostate cancer (mCSPC) using artificial intelligence (AI).. Journal of Clinical Oncology, 2020, 38, 169-169.	1.6	0
104	Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response.. Journal of Clinical Oncology, 2020, 38, TPS267-TPS267.	1.6	0
105	Genomic correlates of response to PD-1 axis inhibitors (IO) in metastatic urothelial cancer (mUC) using explainable artificial intelligence (AI).. Journal of Clinical Oncology, 2020, 38, 570-570.	1.6	0
106	Genomic alterations in visceral versus nonvisceral "metastatic" site tumor tissue in metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2020, 38, 167-167.	1.6	0
107	Impact of somatic SPOP (Speckle-Type POZ protein) mutation (mtSPOP) on response to systemic therapy and survival outcome in men with de novo metastatic castration-sensitive prostate cancer (d-mCSPC).. Journal of Clinical Oncology, 2020, 38, 329-329.	1.6	0
108	Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer. European Urology, 2022, 81, 263-265.	1.9	0